Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract e14040: A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors
Abstract 2545: Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy
Advertisement